Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Muge Cevik
Chloe Orkin

Showing results (1-10 of 260) with videos related to

Pageof 26
Sort By:
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|October 16, 2023
Changing face of mpoxMuge Cevik, Chloe Orkin
Current Opinion in HIV and AIDS|March 13, 2018
Fixed dose darunavir boosted with cobicistat combined with emtricitabine and tenofovir alafenamide fumarateMuge Cevik, Chloe Orkin
Expert Opinion on Investigational Drugs|November 19, 2019
Insights into HIV-1 capsid inhibitors in preclinical and early clinical development as antiretroviral agentsMuge Cevik, Chloe Orkin
Current Opinion in Infectious Diseases|February 2, 2023
Estimating the global impact of coronavirus disease 2019 on people living with HIVJohn Thornhill, Chloe Orkin, Muge Cevik
Open Forum Infectious Diseases|June 27, 2020
Emergent Resistance to Dolutegravir Among INSTI-Naïve Patients on First-line or Second-line Antiretroviral Therapy: A Review of Published CasesMuge Cevik, Chloe Orkin, Paul E Sax
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|January 8, 2021
Gender disparities in coronavirus disease 2019 clinical trial leadershipMuge Cevik, Syed Arefinul Haque, Jennifer Manne-Goehler, et al.
The Lancet. Infectious Diseases|June 25, 2021
SARS-CoV-2 variants and considerations of inferring causality on disease severityMuge Cevik, Sharmistha Mishra
Sexually Transmitted Infections|July 22, 2018
Dolutegravir use in combination with rifampicin-based tuberculosis therapy: 3 years of real-world experience in a large UK teaching hospitalMuge Cevik, Hugh McGann
BMJ Leader|May 18, 2023
Reflections and intersections: disability, 'ableism' and metamodern leadershipChloe Orkin
Open Forum Infectious Diseases|February 14, 2024
Should Human Immunodeficiency Virus Testing Be Replaced With Combined Blood-Borne Virus Testing?Chloe Orkin
Pageof 26

Showing results (1-10 of 260) with videos related to

Sort By:
Pageof 26
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|October 16, 2023
Changing face of mpoxMuge Cevik, Chloe Orkin
Current Opinion in HIV and AIDS|March 13, 2018
Fixed dose darunavir boosted with cobicistat combined with emtricitabine and tenofovir alafenamide fumarateMuge Cevik, Chloe Orkin
Expert Opinion on Investigational Drugs|November 19, 2019
Insights into HIV-1 capsid inhibitors in preclinical and early clinical development as antiretroviral agentsMuge Cevik, Chloe Orkin
Current Opinion in Infectious Diseases|February 2, 2023
Estimating the global impact of coronavirus disease 2019 on people living with HIVJohn Thornhill, Chloe Orkin, Muge Cevik
Open Forum Infectious Diseases|June 27, 2020
Emergent Resistance to Dolutegravir Among INSTI-Naïve Patients on First-line or Second-line Antiretroviral Therapy: A Review of Published CasesMuge Cevik, Chloe Orkin, Paul E Sax
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|January 8, 2021
Gender disparities in coronavirus disease 2019 clinical trial leadershipMuge Cevik, Syed Arefinul Haque, Jennifer Manne-Goehler, et al.
The Lancet. Infectious Diseases|June 25, 2021
SARS-CoV-2 variants and considerations of inferring causality on disease severityMuge Cevik, Sharmistha Mishra
Sexually Transmitted Infections|July 22, 2018
Dolutegravir use in combination with rifampicin-based tuberculosis therapy: 3 years of real-world experience in a large UK teaching hospitalMuge Cevik, Hugh McGann
BMJ Leader|May 18, 2023
Reflections and intersections: disability, 'ableism' and metamodern leadershipChloe Orkin
Open Forum Infectious Diseases|February 14, 2024
Should Human Immunodeficiency Virus Testing Be Replaced With Combined Blood-Borne Virus Testing?Chloe Orkin
Pageof 26